Publications by authors named "A Didelot"
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is far from being fully characterized.
View Article and Find Full Text PDFThe design of new, biomimetic biomaterials is of great strategic interest and is converging for many applications, including in implantology. This study explores a novel approach to improving dental implants. Although endosseous TA6V alloy dental implants are widely used in oral implantology, this material presents significant challenges, notably the prevalence of peri-implantitis.
View Article and Find Full Text PDFObjective: To assess the impact of epilepsy and antiseizure medications (ASMs) on sleep quality in people with epilepsy (PWE).
Methods: An online survey was conducted in France, Germany, Italy, Spain and the UK among PWE taking >1 ASM and matched controls. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).
Article Synopsis
- - The study focuses on lung adenocarcinoma (LUAD) and introduces a miR-200 based RNA signature that helps predict survival rates beyond existing classification methods, especially as therapies are moving to earlier stages of the disease.
- - Using RNA sequencing, researchers identified three different clusters of tumors based on their miR-200 signature, each associated with specific genetic mutations, and assessed various biological processes and immune responses connected to these clusters.
- - The miR-200 signature effectively stratified patients into high- and low-risk groups, showing that those with a higher signature had longer disease-free survival, suggesting its potential for improving prognosis evaluations and guiding treatment plans in LUAD.
Introduction: Epilepsy is a serious neurological disorder affecting the quality of life (QoL) of people with this condition. A survey was conducted in five European countries (France, Germany, Italy, Spain, and the UK) to understand the impact and burden of epilepsy and its treatment on the lives of people with epilepsy (PWE).
Methods: Five hundred PWE (taking >1 antiseizure medication [ASM]) and 500 matched controls completed a 30-minute online questionnaire.